scispace - formally typeset
C

Carl Grunfeld

Researcher at University of California, San Francisco

Publications -  372
Citations -  35694

Carl Grunfeld is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Tumor necrosis factor alpha & Adipose tissue. The author has an hindex of 99, co-authored 368 publications receiving 34037 citations. Previous affiliations of Carl Grunfeld include San Francisco General Hospital & Veterans Health Administration.

Papers
More filters
Journal ArticleDOI

Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host.

TL;DR: APR-induced alterations initially protect the host from the harmful effects of bacteria, viruses, and parasites, however, if prolonged, these changes in the structure and function of lipoproteins will contribute to atherogenesis.
Journal ArticleDOI

Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

TL;DR: In this article, the authors studied plasma lipids, lipoproteins, triglyceride (TG) metabolism, and serum cytokines in three groups: patients with the acquired immunodeficiency syndrome (AIDS) without active secondary infection, patients with evidence of HIV infection but without clinical AIDS (HIV+), and controls.
Journal ArticleDOI

Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters.

TL;DR: Induction of leptin during the host response to infection may contribute to the anorexia of infection, as assessed by immuknoprecipitation and Western blotting.
Journal ArticleDOI

Leptin regulation of the immune response and the immunodeficiency of malnutrition

TL;DR: Low leptin levels occurring during starvation mediate the neuroendocrine and immune dysfunction of starvation, and may represent a protective component of the host response to inflammation.
Journal ArticleDOI

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

TL;DR: In this paper, the authors analyzed paired data in HIV-infected patients before and after beginning antiretroviral therapy that included a PI (PI, N = 20) or lamivudine (3TC) but no PI (3 TC), and a control group on stable regimens that included neither of these agents (CONT: N = 12).